FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:221 July 13, 2006 Number 2

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bresalier, R. S.

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial . In the reported results, the test for proportionality of hazards used linear time rather than the logarithm of time that was specified in the Methods section. Analysis using the logarithm of time leads to the following changes:

The first complete paragraph on page 1097 should have read, "In a post hoc assessment, visual inspection of Figure 2 suggested that the Kaplan–Meier curves separated 18 months after randomization. However, the results of an overall test of the proportional-hazards assumption for the entire 36-month observation period did not reach statistical . . . [Full Text of this Article]

This article has been cited by other articles:

• McGettigan, P., Henry, D. (2006). Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. JAMA 296: 1633-1644 [Abstract] [Full Text]  
• Nissen, S. E., Furberg, C. D., Bresalier, R. S., Baron, J. A. (2006). Adverse Cardiovascular Effects of Rofecoxib. NEJM 355: 203-205 [Full Text]  
• (2005). Risk from Vioxx in a Colorectal-Adenoma Prevention Trial. Journal Watch Cardiology 2005: 2-2 [Full Text]